Evolus, Inc. is a performance beauty company. Its primary market is the cash-pay aesthetic market, which consists of medical products. Its product candidates include Jeuveau and Evolysse. Jeuveau is its commercially available proprietary 900 kilodalton (kDa), purified botulinum toxin type A formulation indicated for the temporary improvement in the appearance of moderate to severe glabellar lines, also known as frown lines, in adults. Jeuveau offers a 900kDa botulinum toxin alternative to BOTOX (onabotulinumtoxinA). Jeuveau is available in the United States, Canada, and European markets. Evolysse is a line of hyaluronic acid dermal fillers which utilizes first-generation cold technology in regulatory development. The line includes a variety of products, including mid face, nasolabial folds, lips and eyes in the United States and Europe. Its product candidates represent two of the product categories within medical aesthetics, injectable neurotoxins, and injectable dermal fillers.
종목 코드 EOLS
회사 이름Evolus Inc
상장일Feb 08, 2018
CEOMr. David Moatazedi
직원 수332
유형Ordinary Share
회계 연도 종료Feb 08
주소520 Newport Center Dr Ste 1200
도시NEWPORT BEACH
증권 거래소NASDAQ Global Market Consolidated
국가United States of America
우편 번호92660-7022
전화19492844555
웹사이트https://www.evolus.com/
종목 코드 EOLS
상장일Feb 08, 2018
CEOMr. David Moatazedi
지난 5년 동안 총
0.00
USD의 배당금이 분배되었습니다.

데이터 없음